ClinicalTrials.gg
Not yet recruitingNCT06279052APT-WILLUpdated Feb 28, 2024

Adolescent Projections During Transition in Prader-Willi Syndrome

An interventional study of Phone interview in Prader-Willi Syndrome, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 15 Years to 20 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
15 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse — 6 open to participants now, 6 under way, 1 of them phase 3. Prader-Willi Syndrome · University Hospital, Toulouse.

Planned enrollment
12th of 14
20 · median 37
Started
2024
the only one that year
No phase
6 of 17
2 open now
Registered
15th of 17
by date

Among the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 6 with no phase, and was the 15th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

6 of the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 15 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Single-center, cross-sectional qualitative study seeking to collect the experience of adolescence and the transition to adulthood of people affected by Prader-Willi syndrome in a population. To do this, the present will carry out a qualitative study with a reflexive thematic analysis of the data collected through semi-structured interviews using an interview guide.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

04

Who can participate

Ages eligible
15 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with genetically confirmed Prader-Willi syndrome
  • Patients affiliated or beneficiaries of a social security system
  • Patients known and followed by the reference center, presenting sufficient intellectual skills to answer the interview questions

Exclusion criteria

Exclusion Criteria:

  • Refusal of family participation (if minor)
  • Refusal of participation by the patient or his guardian (if of legal age)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Phone interview

    Patients will then be contacted by the investigator to arrange a telephone appointment date. On the day of the telephone appointment, the psychiatry intern will call the patient to conduct the interview which will last between 30 and 60 minutes. At the end of the telephone interview, the patient's participation in the research will end.

    Behavioral: Phone interview

Interventions

  • BehavioralPhone interview

    Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved

06

What researchers measure

Primary outcomes

  1. Experience of the disease and aspirations regarding the future

    The main objective of this study is to explore their experience of the disease and their aspirations regarding their future in a population of older adolescents and young adults with Prader-Willi syndrome. A questionnaire created by the clinical investigator containing personal questions will be applied to all patients. There is no scale.

    Time frame: 1 hour

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Dec 2024, 9 months later.

Of 19 interventional studies with no phase under Prader-Willi Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 26, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06279052
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Grégoire BENVEGNU
Contact
benvegnu.g@chu-toulouse.fr
05 34 55 86 78 ext. +33
Grégoire BENVEGNU
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion